Alkem Laboratories And Gallantt Ispat Record Block Deals Worth ₹428.7 Crore As Shares Show Mixed Movement On NSE

Alkem Laboratories and Gallantt Ispat recorded block deals worth ₹428.7 crore on NSE, while both stocks saw mixed movements. Read more for details.
Alkem Laboratories Ltd and Gallantt Ispat Ltd saw block deals worth a combined ₹428.7 crore on the National Stock Exchange (NSE) on Tuesday. Of this, ₹301.90 crore worth of shares changed hands in Alkem Laboratories, while the Gallantt Ispat transaction was valued at an estimated ₹126.8 crore. Both stocks moved in different directions during the session.
How Did Alkem Laboratories And Gallantt Ispat Shares Trade?
The Alkem Laboratories block deal involved 5.98 lakh shares changing hands at ₹5,050 apiece. The transaction took the total deal value to ₹301.90 crore.
Alkem Laboratories shares were trading 1.62% higher at ₹5,219 at 10:28 AM, following the transaction.
Gallantt Ispat, on the other hand, saw its shares decline 1.10% to ₹537.15. The estimated value of its block deal stood at ₹126.8 crore.
The two transactions formed part of the day's NSE block deals, with investors keeping an eye on large-volume trades alongside regular market activity.
Block deals are usually associated with institutional investors and large shareholders. However, the identity of buyers and sellers and the reason behind a transaction are important details when assessing what such activity could mean for a stock.
What Is Happening With Alkem Laboratories' Business?
Sales from Alkem's branded formulations business increased 12.1% in Q2 FY27, helped by demand for chronic therapies, although the trade generics segment had a slower quarter. Competition and tighter credit availability weighed on sales in this business.
The US market remained difficult. Alkem reported 10% volume growth, but a 16% price decline in one product offset much of that gain. Despite selling higher volumes, the company continued to face pressure on realisations in the US market.
What Should Investors Track Next?
The performance of its domestic formulations business will be worth tracking as the company deals with slower growth in trade generics and pricing pressure in the US.
Gallantt Ispat investors, meanwhile, will be watching the company's business developments and stock performance amid changing market conditions.
Tuesday's block deals add to the day's trading activity, but the transactions alone do not establish a change in either company's business outlook. The next set of results and company disclosures should offer more clarity on the direction of both businesses.
This article is for informational purposes only and should not be considered investment advice from Kotak Neo. For compliance T&C and disclaimers, Visit www.kotakneo.com/disclaimer

Vishwa has spent 10+ years across fintech and FMCG doing what most people miss, connecting the dots, catching trends before they trend, and finding the angle nobody else thought to ask about.
At Kotak Neo, she drives content strategy for neoshorts, Kotak News Desk, and Investing Guide, turning market noise into something worth reading.
When she's not decoding markets, she trades charts for canvases, chasing art, painting, and architecture across cities she's yet to explore.
Right Tools, Rich Insights










